Bullous Pemphigoid Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2022-2032),|Key Companies – Gilead Sciences, Takeda, Pfizer, GlaxoSmithKline

 Breaking News
  • No posts were found

Bullous Pemphigoid Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2022-2032),|Key Companies – Gilead Sciences, Takeda, Pfizer, GlaxoSmithKline

May 02
17:23 2023
Bullous Pemphigoid Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2022-2032),|Key Companies - Gilead Sciences, Takeda, Pfizer, GlaxoSmithKline
DelveInsight Business Research LLP
DelveInsight’s “Bullous Pemphigoid (BP) – Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the BP, historical and forecasted epidemiology as well as the BP market trends in the United States, the EU4 and the UK and Japan.

DelveInsight’s “Bullous Pemphigoid (BP) – Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the BP, historical and forecasted epidemiology as well as the BP market trends in the United States, the EU4 and the UK and Japan.

Bullous Pemphigoid Overview

According to the Cornea Research Foundation of America (2022), Bullous keratopathy is a condition where the cornea becomes permanently swollen. This occurs because the inner layer of the cornea, the endothelium, has been damaged and is not pumping fluid properly. The cause of endothelial damage could be trauma, glaucoma, or inflammation after eye surgery. The causes of bullous keratopathy have changed over the last two decades. Twenty years ago, the most common reason for bullous keratopathy was complications from cataract surgery with or without problems from intra-ocular lenses. Cataract surgery techniques and intra-ocular lens implants have improved dramatically over this period. Corneal problems are now less common after cataract surgery. Currently, one of the most common reasons for developing bullous keratopathy, or secondary corneal decompensation, is related to problems due to glaucoma surgery. Subepithelial fluid-filled bullae form on the corneal surface as the corneal stroma (the deeper dense connective tissue layer of the cornea) swells, leading to decreased visual acuity, loss of contrast, glare, and photophobia. Sometimes bullae rupture, causing pain and foreign body sensation. Bacteria can invade a ruptured bulla, leading to a corneal ulcer.

Bullous Pemphigoid  Epidemiology Insights

  • In a study by Shimazaki et al. (2007), the most common cause of bullous keratopathy was cataract surgery (pseudophakic or aphakic BK: PBK/ABK, n=428, 44.4%), followed by laser iridotomy (LI, n=225, 23.4%), glaucoma surgery other than LI (n=51, 5.3%), trauma (n=40, 4.2%), glaucoma (n=26, 2.7%), and vitrectomy (n=21, 2.2%). 

  • According to the American Academy of Ophthalmology (2022), it is estimated that 1-2 % of people undergoing cataract surgery will develop persistent post-operative edema. Old surgical techniques and intraocular lens designs were associated with higher numbers of postoperative corneal edema. Preoperative endothelial cell count and surgical trauma are the most important factors for developing PBK. 

Click here to learn more about the Bullous Pemphigoid Market Landscape

The Report Covers the Bullous Pemphigoid Epidemiology Segmented by:

  • Bullous Pemphigoid prevalent cases 

  • Bullous Pemphigoid diagnosed cases 

  • Bullous Pemphigoid treatment cases 

  • Bullous Pemphigoid  incident cases 

  • Bullous Pemphigoid cases based on age 

 

Key Companies Working in the Bullous Pemphigoid Market

  • Gilead Sciences 

  • Takeda 

  • Pfizer 

  • GlaxoSmithKline 

  • And many others 

Bullous Pemphigoid Therapies Covered and Analyzed in the Report:

  • Filgotinib

  • CT-P13

  • Remicade

  • Infliximab

  •  MT-1303

Learn more about the Key Companies and Emerging Therapies in the Bullous Pemphigoid    Market.

 Table of Contents 

  1. Key Insights 

  2. Bullous Pemphigoid  Introduction 

  3. Executive Summary of Bullous Pemphigoid      

  4. Disease Background and Overview

  5. Epidemiology and patient population

  6. Bullous Pemphigoid  Emerging Therapies

  7. Bullous Pemphigoid  Market Outlook

  8. Market Access and Reimbursement of Therapies

  9. Market Drivers 

  10. Market Barriers 

  11. Appendix

  12. Report Methodology

  13. DelveInsight Capabilities

  14. Disclaimer

Learn about the detailed offerings of the report @ Bullous Pemphigoid Market Outlook.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Adya Kaul
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting

Categories